Journal article
[Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of bevacizumab versus ranibizumab for patients with neovascular age-related macular degeneration (AMD) in China.
METHODS: A Markov model was constructed to compare cost per quality-adjusted life year of bevacizumab with ranibizumab in patients with neovascular AMD. In the Markov model, with cycle length of 3 months and time horizon of 10 years, three health states were defined by visual acuity. One …
Authors
Li H; Li X; Xie F
Journal
Chinese Journal of Ophthalmology, Vol. 50, No. 6, pp. 426–433
Publication Date
June 2014
ISSN
0412-4081